Strategic Positioning of Bioimpression Technology As a Scalable DFU Solution in Colombia
Author(s)
JUAN C. FERNANDEZ MERCADO, MBA, MSc, PhD, MD1, Nelson Alvis-Guzman, MPH, PhD, MD2, Lácides José Barrera C, Sr.3.
1UNIVERSIDAD DE CARTAGENA, Cartagena, Colombia, 2Universidad de Cartagena - ALZAK Foundation, Cartagena, Colombia, 3Gerente de Valor y Acceso, ANNAR Health Technologies – Colombia, Bogotá, Colombia.
1UNIVERSIDAD DE CARTAGENA, Cartagena, Colombia, 2Universidad de Cartagena - ALZAK Foundation, Cartagena, Colombia, 3Gerente de Valor y Acceso, ANNAR Health Technologies – Colombia, Bogotá, Colombia.
OBJECTIVES: To evaluate the feasibility and strategic positioning of bioimpression technology as a scalable, high-impact solution for diabetic foot ulcer (DFU) care in Colombia, with a focus on technology adoption in public and private healthcare institutions.
METHODS: We used a health technology assessment (HTA) approach combining clinical effectiveness, cost-benefit ratio, user acceptability, and alignment with national health goals. Data were gathered from regional IPSs in the Caribbean and validated through stakeholder interviews (managers, clinicians, patients).
RESULTS: The bioimpression technology was highly accepted by clinicians and patients, with 87% reporting high satisfaction and confidence in healing outcomes. It demonstrated cost-efficiency, adaptability, and high impact in resource-limited settings. Policy alignment was confirmed with Colombia's Integrated Health Care Model (MIAS) and chronic disease programs, facilitating potential inclusion in future Capita-PGP contracts. Stakeholders identified it as an enabler of the quintupla meta in health: clinical outcomes, patient experience, cost efficiency, clinician satisfaction, and equity.
CONCLUSIONS: Bioimpression technology represents a viable and strategically positioned innovation for chronic wound care in Colombia. Its alignment with national health policies and adaptability to public and private IPSs supports its adoption at scale. It can serve as a platform for innovation in intermediate-level health services and is suitable for inclusion in EPS care pathways under value-based contracting models.
METHODS: We used a health technology assessment (HTA) approach combining clinical effectiveness, cost-benefit ratio, user acceptability, and alignment with national health goals. Data were gathered from regional IPSs in the Caribbean and validated through stakeholder interviews (managers, clinicians, patients).
RESULTS: The bioimpression technology was highly accepted by clinicians and patients, with 87% reporting high satisfaction and confidence in healing outcomes. It demonstrated cost-efficiency, adaptability, and high impact in resource-limited settings. Policy alignment was confirmed with Colombia's Integrated Health Care Model (MIAS) and chronic disease programs, facilitating potential inclusion in future Capita-PGP contracts. Stakeholders identified it as an enabler of the quintupla meta in health: clinical outcomes, patient experience, cost efficiency, clinician satisfaction, and equity.
CONCLUSIONS: Bioimpression technology represents a viable and strategically positioned innovation for chronic wound care in Colombia. Its alignment with national health policies and adaptability to public and private IPSs supports its adoption at scale. It can serve as a platform for innovation in intermediate-level health services and is suitable for inclusion in EPS care pathways under value-based contracting models.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
MT39
Topic
Economic Evaluation, Medical Technologies, Organizational Practices
Disease
Biologics & Biosimilars, Diabetes/Endocrine/Metabolic Disorders (including obesity), Personalized & Precision Medicine